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Hepatitis A virus (HAV) is the most common cause of viral hepatitis worldwide. Infection with 
HAV is vaccine preventable, however, a vaccine against HAV is not included in the Expanded 
Programme on Immunization in South Africa (SA). South Africa was considered to be a high 
endemic country for hepatitis A in the past, hence there was no need for routine immunization 
against the virus. Our hypothesis is that SA is changing from high to intermediate endemic 
setting for hepatitis A. To test our hypothesis, we conducted a cross-sectional seroprevalence 
study in the 1-7 year age group in the Western Cape Province. Our samples for this study 
were from specimens, collected between August and October 2015,  sent for routine diagnosis 
to referral hospitals in the Western Cape Province. We tested remaining serum of 482 samples 
sent for routine tests. A Siemens enzyme immunoassay was used to test for hepatitis A 
antibodies. We also analysed hepatitis A test results from the National Health Laboratory 
Services (NHLS) Disa*Lab database at Groote Schuur hospital from 2009–2014, as well as 
hepatitis A surveillance data from the National Institute for Communicable Diseases (NICD) 
from 2009-2014, to look at the past hepatitis A prevalence trend. Our cross-sectional study 
showed the seroprevalence to be 44.1% in the 1-7 year age group. The NHLS data showed 
a seroprevalence of <90% up to age 10 years, indicating intermediate endemicity. The NICD 
data showed that a substantial number of symptomatic hepatitis A infections occurred in the 
7-40 year age group, suggesting an increasing proportion of a susceptible population to HAV 
infection. Taken together, these results indicate the need for further studies designed to aid 
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Chapter one: Literature review 
Introduction 
Hepatitis A infection is caused by hepatitis A virus, a member of the Hepatovirus genus of the 
family Picornaviridae, one of 12 genera (Figure 1). Hepatitis A virus (HAV) is a non-enveloped 
single-stranded positive sense RNA virus (1, 2). HAV infects humans and nonhuman primates 
like African green monkeys. However the disease is usually milder in nonhuman primates (3).  
 
 
Figure 1.  Phylogenetic tree showing 12 Genera of Picornaviridae. The figure is from Field’s Virology, 6th edition, 
volume 1, chapter 19, page 551 (Figure 19.1), Permission for use of the figure in the dissertation was granted by 
Wolters Kluwer Health (Publishers). 
 
Hepatitis A virus is very stable at low pH and is highly thermostable (3). Infectivity can be 
destroyed at temperatures above 85ºC, however HAV infectivity is highly resistant to drying, 
detergents and organic solvents. In addition HAV can survive for several days to months in 
contaminated water sources and food (3). There are reports suggesting that even steaming 
might not be able to destroy HAV, as outbreaks of hepatitis A have been reported following 
ingestion of partially cooked bivalve molluscs (3). 
Hepatitis A virus is the most common cause of acute viral hepatitis worldwide (2). The virus is 
responsible for approximately 1.4 million new infections each year (4-6). There are many 
factors influencing the epidemiology of HAV. For example, as countries improve their levels 
of sanitation and hygiene, the rates of HAV infection decline and the geographic distribution 
of HAV infection changes (3). Additionally, age, gender, and the illicit use of drugs may play a 
role in hepatitis A disease severity (1, 3, 7). 
Transmission of HAV is via the faecal-oral route, either through an infectious person, or by 
ingestion of contaminated food or water (1, 8). Sexual contact has also been implicated (3). 
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Transmission of the virus has also been reported to occur during administration of high purity, 
solvent-detergent-treated clotting factor concentrates (3). For example, an outbreak of 
hepatitis A occurred between June 1993 and February 1994 in haemophiliacs in South Africa 
who received infusions of factor VIII concentrate (9). The factor VIII concentrate was treated 
with intermediate-purity solvent/detergent method, which does not inactivate non-enveloped 
viruses (9). 
There are several risk factors for HAV infection (1). The risk factors include low socioeconomic 
status, a larger household size and overcrowding in rural areas, limited access to clean water 
sources and poor sanitation facilities (4, 7). High risk population groups include those who 
travel or emigrate from a HAV non-endemic region to an endemic region (1), patients with 
chronic liver diseases, men who have sex with men (MSM), military recruits, illicit drug users 
(injecting or noninjecting) and persons with clotting factor disorders (3).  
Hepatitis A infection is vaccine preventable. The vaccine against HAV, when administered at 
least 2 weeks before travel is effective against infection for most travellers. However, among 
individuals whose immune response to the vaccine may not be adequate, like the 
immunocompromised, persons with chronic liver disease, adults older than 40 years of age, 
and who are planning travel to an endemic area, the simultaneous administration of the 
vaccine with immunoglobulin M (0.02-0.06ml/kg) should provide optimal protection. It is 
important that separate syringes and different injection sites be used (3). 
Infection with HAV occurs at an early age, and close to 100% of children are infected in the 
first decade of life, in populations with poor or no sanitation and overcrowded living conditions 
as thought to be in majority of African countries (3). On the other hand, a decrease in hepatitis 
A seroprevalence has been noted in developing nations that have improved sanitation and 
hygiene. In settings of high HAV endemicity, improved sanitation and hygiene, coupled with 
overall economic developments can give rise to a susceptible population and epidemics may 
occur if the susceptible population has accidental exposure to HAV (3). 
Currently, HAV circulates worldwide as a total of 6 genotypes (3, 10). Three genotypes (I, II, 
III) are divided into subtypes A and B (3, 11, 12). Genotypes I, II,III are human strains (12) 
with subgenotype IA (10, 11) and genotype III being the most prevalent worldwide (3, 10). 
Infection with any of the genotypes usually results in lifelong immunity against all strains of 
hepatitis A. A study conducted in SA between 1982 and 1996 looked at the molecular 
epidemiology of HAV strains and concluded that SA had predominantly genotype I, with most 
clustering in subgenotype IB, and the rest in subgenotype IA (13). 
In children less than 6 years old, infection with HAV often presents asymptomatically and 
results in lifelong immunity (1, 14). However, in children older than 6 years as well as 
adolescents and adults, hepatitis A infection can present with jaundice and other potentially 
severe symptoms (1, 5, 8). A typical course of acute infection has 4 clinical phases: (a) 
incubation or preclinical period, (b) prodromal or pre-icteric stage, (c) icteric phase, and (d) 
convalescent period (3). Atypical manifestations of hepatitis A include cholestasis, induction 
of type 1 autoimmune hepatitis, extrahepatic manifestations and relapsing hepatitis (3). 
Extrahepatic manifestations are unusual and include arthralgia, arthritis, haemolysis, 
leukocytoclastic vasculitis, membranoproliferative glomerulonephritis, and pancreatitis. 
Fulminant hepatitis, caused by severe liver necrosis during acute hepatitis A infection, occurs 
occasionally, and is characterized by sudden onset high fever, abdominal pain, vomiting, 
jaundice and the development of encephalopathy. The associated mortality rate is high . 
Anti-HAV IgM antibodies are detectable in serum soon after acute infection, and can remain 
detectable for 6 months or longer in some instances, as indicated in Figure 2. IgM reflects 
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current or recent infection. In contrast, the presence of anti-HAV IgG antibodies in serum 
confirm past infection or vaccination, and usually indicates lifelong immunity. Serological 
testing for anti-hepatitis A total antibodies (vaccination, past infection or recent infection), anti-
hepatitis A IgM antibodies (recent or acute infection), and anti-hepatitis A IgG antibodies (past 
infection or vaccination), are available for laboratory diagnosis. 
 
  
Figure 2. Clinical and immunological events during HAV infection. The figure is adapted from Field’s Virology 6th 




There is no specific treatment for HAV infection and management usually remains supportive. 
The most important control measure is proper handwashing to prevent faecal contamination 
by infected individuals. Management of fulminant hepatitis includes immediate transfer of the 
patient to a liver transplant facility and aggressive management of complications. This 
improves the survival rate of the patient. Orthotopic liver transplantation (OLT) or auxiliary 
partial OLT in severely affected patients with fulminant hepatitis, leads to 1- year survival rates 
of 80% or more (15). 
Acute HAV infection is vaccine preventable (16). There are two types of hepatitis A vaccines 
currently being used worldwide, formaldehyde inactivated vaccines and live attenuated 
vaccines (17, 18). The World Health Organization (WHO) 2012 position paper on hepatitis A 
vaccines states that both the inactivated and live attenuated vaccines are safe and highly 
immunogenic, and that in most cases these vaccines will generate long-lasting, and possibly 
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lifelong protection against HAV in both healthy children and adults (18). Childhood vaccination 
that provides effective long-lasting immunity into adulthood, is recommended in endemic 
areas, for protection and elimination of HAV in these areas (19). A more than 95% decrease 
of reported hepatitis A cases were observed in Israel from 1993-2004, and maintained through 
2012. This was thought to be due to the universal use of hepatitis A vaccines, and 
enhancements in childhood immunization schedules (19).  
Inactivated hepatitis A vaccines were developed in the early 1990s, and thereafter licensed 
for use in the mid-1990s (19). There are alum–or influenza virosome-adjuvanted, 
formaldehyde-inactivated vaccines (Havrix 720, Vaqta, Avaxim, and Epaxal). Both these 
vaccines are available worldwide. There are also freeze-died, live attenuated vaccines that 
are used primarily in China, and have recently been introduced into India.  Most of the vaccines 
are produced by growing HAV strains in human diploid fibroblast cell cultures. Purification of 
the cell extracts is then done, followed by inactivation using formaldehyde, and finally 
adsorption onto aluminium hydroxide adjuvant (19). HAV-specific antigen has also been 
combined with other vaccines like hepatitis B vaccine (Twinrix, Twinrix Junior, Ambirix), or 
typhoid vaccines (ViATIM, Vivaxim, Hepatyrix). The HAV vaccines do not induce antigenic 
competition with the other vaccines, and the frequency of adverse events is not increased (3). 
Two intramuscular injections of the inactivated vaccines are required 6 to 12 months apart 
(interval can be extended to 36 months), and all the inactivated vaccines display similar 
immunogenicity profile.  However, the WHO suggest that in healthy individuals, comparable 
effectiveness has been achieved with a single dose. The minimum age of HAV vaccination is 
one year. According to estimates using kinetic models, protective levels of neutralizing 
antibodies could persist for 20 years or longer. At present the vaccine is only recommended 
for persons 1 year of age and older. The bivalent hepatitis A and B vaccine, Twinrix, is 
recommended for susceptible persons 18 years and older. The live attenuated hepatitis A 
vaccines used in China over the last decade, have be shown to be safe and immunogenic. 
Seroprotective levels for more than 10 years have been achieved from a single-dose 
immunization schedule, and decreased infection rates was observed in the unvaccinated 
population, indicating herd immunity (3).  
A phase 2 follow-up study was recently conducted in Israel to assess the long-term 
immunogenicity of Epaxal Junior which is a paediatric dose of an aluminium-free inactivated 
hepatitis A vaccine, in children receiving routine childhood vaccination (19). The formalin-
inactivated HAV is associated with immunopotentiating resconstituted influenza virosomes in 
Epaxal, and is therefore based on a different adjuvant system. The standard doses of Epaxal 
offers long-term seroprotection which persists for about 30 years. Epaxal Junior is also 
reported to have satisfactory immune responses and safety profiles in children 1-16 years of 
age, and in toddlers (19).   
For post exposure prophylaxis, the Advisory Committee on Immunization Practices (ACIP) in 
the US recommends the use of the vaccine and/or immunoglobulin, in the following persons 
and situations: (a) close personal contact including household and sexual ( consider vaccine 
alone, or vaccine and immunoglobulin if the contact shared illicit drugs with the case), (b) 
outbreaks in childcare facilities, (c) common-source exposure (food handlers of index worker 
and patrons if identified and treated within 2 weeks of exposure), (d) outbreaks confirmed in 
schools, hospitals and work settings (3).  
In 1988 in Shanghai, China, an explosive outbreak of hepatitis A infection was reported with 
over 300,000 cases and 47 deaths. The outbreak was associated with the consumption of raw 
clams, and again, represents an example of the magnitude of hepatitis A infection in a 
susceptible population (17). 
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Infection with HAV late in childhood or in adulthood, may also require hospitalisation, and may 
cause absenteeism from school or work for prolonged periods of time. There is a rising risk of 
fulminant hepatic failure, and the case-fatality ratio can reach 2.1% among adults above the 
age of 40 years (19). In terms of both direct medical costs and loss of productivity, infection at 
an older age can therefore be expensive (1, 7). A study conducted in Brazil in 2012 used an 
age and time dependant dynamic model, and concluded that a universal immunization 
programme for hepatitis A would result in a 64% decrease in the number icteric hepatitis A 
cases, a 59% reduction in deaths caused by the disease, and a 62% decrease in life years 
lost, in a national perspective (20). 
Countries are classified according to the following levels of hepatitis A endemicity: (21, 22) 
1. high (≥90% by age 10 years) 
2.  intermediate  (≥50% by age 15 years, with <90% by age 10 years) 
3.  low (≥50% by age 30 years, with <50% by age 15)  
4.  very low (<50% by age 30 years)).  
South Africa is classified as a high HAV endemic country. The WHO co-ordinated a systematic 
review in 2010 (1) and reported the distribution of hepatitis A seroprevalence in SA, classifying 
the country as a highly endemic one. The WHO systematic review included studies done in 
South Africa from 1981 – 1996, including those by Taylor et al. in 1995 (23), as well as by 
Abdool Karim in 1993 (24). The WHO systematic review reported differences in hepatitis A 
seroprevalence between the different population groups in SA. It is very likely the difference 
in socioeconomic status between these ethnic groups could partly explain the observed 
variability of hepatitis A seroprevalence. 
To the best of our knowledge, the most recent study on Hepatitis A in the Western Cape was 
published by Solomons et al. in 2008 (14). This study was conducted from 2001-2004 at 
Tygerberg Children’s Hospital, and indicated that the median population incidence of 
serologically proven HAV infection was  45.4/100 000/year (14). This study included only 
serum IgM positive results. This reported incidence is higher than that recommended as a 
threshold (20/100 000/year), for introducing universal or targeted vaccination into the 
immunization schedule (14, 25).  
The 2010 WHO review also indicated that sub-Saharan Africa had one of the highest hepatitis 
A seroprevalence rates in the world. This classified the whole continent as a high hepatitis A 
endemic region, where nearly all older children and adults tested, showed acquisition of 
natural immunity against the virus (26). 
Currently none of the countries in the WHO Afro region have included HAV vaccine in the 
routine Expanded Programme on Immunization (EPI)  because it is assumed that exposure 
to, and infection with the virus, is widespread at an earlier stage in life 
(http://apps.who.int/immunization_monitoring/globalsummary/schedules). However, there are 
studies reporting a decrease, in exposure and infection at an early age, in some countries 
within Africa (1, 4, 7, 26). 
There are several factors that may contribute to a lower infection rate at an earlier age. Among 
these factors are: improved socioeconomic status (SES) (7), higher education levels, 
increased access to clean water and better sanitation (27). For example a study was done to 
describe hepatitis A outbreak in Roma in north eastern Greece, looking at 124 cases of 
hepatitis A infection, occurring in three prefectures, between 2 July and 30 November 2007. 
The study conclusions were that it is probable that Roma communities experienced a relative 
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improvement in sanitary conditions, and a switch from high to intermediate level of HAV 
endemicity was made. This could be an explanation for the occurrence of the outbreak that 
affected mainly the children and adolescents. Following the findings of this study in Greece, 
vaccination against HAV as a preventative measure was suggested (28). 
South Africa (SA), in the last two decades, has made tremendous progress in improving water 
sources and sanitation (29), although studies conducted in rivers and source water dams in 
Gauteng from 1997-2000 and the Eastern Cape Province’s Buffalo river and three water 
source dams on its route, revealed a high potential risk of HAV infection to persons using the 
surface dam and river water for domestic and recreational purposes (30, 31). It is presumed 
that hepatitis A infection occurs early in life, and therefore a vaccine against hepatitis A 
infection is not included in the EPI of the country. Thus, hepatitis A associated morbidity and 
mortality may increase as the age of HAV infection increases (2, 4, 7, 26, 27). 
In resource-poor regions, socioeconomic development and improvement in sanitation may 
lead to a change from high to intermediate HAV endemicity. This is known as “epidemiologic 
transition” (32). Such a transition paradoxically increases the morbidity and mortality 
associated with HAV infection. Recently, Melhem et al showed that the Middle East and North 
African countries, similar to many other areas in the world, demonstrate an epidemiological 
shift in the age of hepatitis A infection, from that of a younger age group to that of an older 
age group (33). This may be associated with increased outbreaks among the younger more 
susceptible age groups.  
Our hypothesis is that SA is changing from high to intermediate endemic setting for hepatitis  
A. We tested the hypothesis of our study by conducting a pilot cross-sectional study in the 
Western Cape Province aimed at assessing the current hepatitis A seroprevalence. We also 
assessed the trend in hepatitis A seroprevalence in the Western Cape, by analysing Disa*Lab 
data from the Groote Schuur hospital database, looking at hepatitis A anti-IgG antibody test 
results from 2009 to 2014. Disa*Lab is a laboratory information management system that was 
used by the NHLS in the past, based on distributed computer networks. In addition, we 
analysed surveillance data from the National Institute for Communicable Diseases (NICD), 
















1. The World Health Organization. the Global Prevalence of Hepatitis A Virus Infection 
and Susceptibility: A systematic review (WHO/IVB/10.01), http://www.whoint/ivb 
documents; (accessed 17.02.2017) 
2. Harrison TJ, Dusheiko GM, Zuckerman AJ. Hepatitis viruses. In: Zuckerman AJ, 
Banatvala JE, Schoub BD, Grifiths PD, Mortimer P, editors. Principles and Practice 
of Clinical Virology, 6th ed. Chichester: Wiley Blackwell. p.273-320. 
3. Hollinger FB, Emerson SU. Hepatitis A virus. In Knipe DM, Howley PM, Cohen JI, 
Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B, editors. Fields Virology, 
6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2013. Vol 1: 
p.550-581. 
4. Jacobsen KH, Koopman JS. The effects of socioeconomic development on 
worldwide hepatitis A virus seroprevalence patterns. International journal of 
epidemiology. 2005;34(3):600-9. 
5. Saha S-K. Community-based cross-sectional seroprevalence study of hepatitis A in 
Bangladesh. World Journal of Gastroenterology. 2009;15(39):4932. 
6. Kanyenda TJ, Abdullahi LH, Hussey GD, Kagina BM. Epidemiology of hepatitis A 
virus in Africa among persons aged 1-10 years: a systematic review protocol. 
Systematic Reviews. 2015;4:129. 
7. Jacobsen KH. Hepatitis A virus in West Africa: Is an epidemiological transition 
beginning? Nigerian medical journal : Journal of the Nigeria Medical Association. 
2014;55(4):279-84. 
8. Savage RD, Rosella LC, Brown KA, Khan K, Crowcroft NS. Underreporting of 
hepatitis A in non-endemic countries: a systematic review and meta-analysis. 
BioMed Central Infectious Diseases. 2016;16(1):281. 
9. Kedda M-A,  et al. An outbreak Of Hepatitis A Among South African Patients With 
Haemophilia: Evidence Implicating Contaminated Factor VIII Concentrate as the 
Source. Hepatology.1995;22(5):1363-67. 
10. Costa-Mattioli M, Di Napoli A, Ferre V, Billaudel S, Perez-Bercoff R, Cristina J. 
Genetic variability of hepatitis A virus. Journal of General Virology. 2003;84:3191-
201. 
11. Lu L, Ching KZ, de Paula VS, Nakano T, Siegl G, Weitz M, et al. Characterization of 
the complete genomic sequence of genotype II hepatitis A virus (CF53/Berne 
isolate). Journal of General Virology. 2004;85(Pt 10):2943-52. 
12. Robertson BH JR, Khanna B, Totsuka A, Nainan OV, Siegl G, et al. Genetic 
relatedness of hepatitis A strains recovered from different geographical regions. 
Journal of General Virology. 1992;73(Pt 6):1365-77. 
13. Taylor MB. Molecular Epidemiology of South African Strains of Hepatitis A 
Virus:1982-1996. Journal of Medical Virology. 1997;51:273-79. 
14. Solomons RS, Rabie H, Nel ED, Cotton MF. An overview of hepatitis A at Tygerberg 
Children's Hospital. South African Journal of Child Health. 2008;2(2):43-5. 
15. Polson J, Lee WM, American Association for the Study of Liver D. AASLD position 
paper: the management of acute liver failure. Hepatology. 2005;41(5):1179-97. 
16. Lazcano-Ponce E, Conde-Gonzalez C, Rojas R, DeAntonio R, Romano-Mazzotti L, 
Cervantes Y, et al. Seroprevalence of hepatitis A virus in a cross-sectional study in 
Mexico: Implications for hepatitis A vaccination. Human vaccines & 
immunotherapeutics. 2013;9(2):375-81. 
17. Verma R, Khanna P. Hepatitis A vaccine should receive priority in National 
Immunization Schedule in India. Human vaccines & immunotherapeutics. 
2014;8(8):1132-4. 
 14 
18. The World Health Organization. Hepatitis A vaccines-July 2012. WHO position 
paper. Summary, http://www.who.int/immunization/position papers/PP hep Ajuly2012 
summary.pdf ; 2012 (accessed 02.01.2017. 
19. Dagan R, Ashkenazi S, Livni G, Go O, Bagchi P, Sarnecki M. Long-term Serologic 
Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis 
A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age.  
The Pediatric Infectious Disease Journal. 2016;35(7):e220-8. 
20. Sartori AM, et al. Cost-effectiveness analysis of universal childhood hepatitis A 
vaccination in Brazil: Regional analyses according to the endemic context. Vaccine. 
2012;30(2012):7489– 97. 
21. Lazcano-Ponce E, Conde-Gonzalez C, Rojas R, DeAntonio R, Romano-Mazzotti L, 
Cervantes Y, et al. Seroprevalence of hepatitis A virus in a cross-sectional study in 
Mexico. Human vaccines & immunotherapeutics. 2014;9(2):375-81. 
22. The World Health Organization. STEPS Sample Size calculator and Sampling 
Spreadsheet ,http://www.who.int/chp/steps/resources/sampling/en/ ;2017 (accessed 
17.02.2017).  
23. Taylor MB,  Becker PJ, Van Rensburgh EJ, Harris BN, Baily IW, Grabouw WO. A 
serosurvey of waterborne pathogens amongst canoeists in South Africa. 
Epidemiology & Infection. 1995;115(2):299-307. 
24. Abdool Karim SS CA. Sero-epidemiology of hepatitis A in black South African 
children. South African Medical Journal. 1993(83):748-9. 
25. Centres for Disease Control and Prevention. Prevention of hepatitis A through active 
or passive immunization. Morbidity and Mortality Weekly Report. 2006;55(RR07):1-
23. 
26. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world 
region, 1990 and 2005. Vaccine. 2010;28(41):6653-7. 
27. Afegbua SL, Bugaje MA, Ahmad AA. Seroprevalence of hepatitis A virus infection 
among schoolchildren and adolescents in Kaduna, Nigeria. Transactions of the Royal 
Society of Tropical Medicine and Hygiene. 2013;107(10):627-30. 
28. Vantarakis A et al. An outbreak of hepatitis A in Roma populations living in three 
prefectures in Greece. Epidemiology & Infection. 2010(138(2010)):1025-31. 
29. The World Bank Databank. Improved sanitation facilities (% of population with 
access) for South Africa, http://www.data.worldbank.org/ ; 2016 (accessed 
17.02.2017). 
30. Venter JME, van Heerden J, Vivier JC, Grabouw OK, Taylor MB. Hepatitis A virus in 
surface water in South Africa: what are the risks? Journal of Water and Health. 
2007(05.2):229-40. 
31.       Chigor VN, Sibanda T, Okoh AI. Assessment of the risks for human health of 
adenoviruses, hepatitis A virus, rotaviruses and enteroviruses in the Buffalo River 
and three source water dams in the Eastern Cape. Food Environ Virol. 2014;6(2):87-
98. 
32. Aggarwal R, Goel A. Hepatitis A: epidemiology in resource-poor countries. Current 
Opinion in Infectious Diseases. 2015;28(5):488-96. 
33. Melhem NM, Talhouk R, Rachidi H, Ramia S. Hepatitis A virus in the Middle East 








Hepatitis A seroprevalence in South Africa. Are we in 
epidemiological transition?  
 
Annabel Enocha, Diana R Hardiea, Monique I Anderssonb, Gregory D 
Husseyc, Benjamin M Kaginac 
aUniversity of Cape Town (UCT),  Division of Medical Virology, Department of Pathology, Anzio Road, 
Observatory, Cape Town, South Africa 
bInfectitious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK 
cVaccine for Africa Initiative (VACFA) and School of Public Health & Family Medicine, University of 
Cape Town, Anzio Road, Observatory, Cape Town, South Africa 
Corresponding author. 
E-mail address: annabelenoch@gmail.com (A Enoch) 
 
Abstract 
Hepatitis A virus (HAV) is the most common cause of viral hepatitis worldwide. Infection with 
HAV is vaccine preventable, however, a vaccine against HAV is not included in the Expanded 
Programme on Immunization in South Africa (SA). South Africa was considered to be a high 
endemic country for hepatitis A in the past, hence there was no need for routine immunization 
against the virus. Our hypothesis is that SA is changing from high to intermediate endemic 
setting for hepatitis A. To test our hypothesis, we conducted a cross-sectional seroprevalence 
study in the 1-7 year age group in the Western Cape Province. Our samples for this study 
were from specimens, collected between August and October 2015,  sent for routine diagnosis 
to referral hospitals in the Western Cape Province. We tested remaining serum of 482 samples 
sent for routine tests. A Siemens enzyme immunoassay was used to test for hepatitis A 
antibodies. We also analysed hepatitis A test results from the National Health Laboratory 
Services (NHLS) Disa*Lab database at Groote Schuur hospital from 2009–2014, as well as 
hepatitis A surveillance data from the National Institute for Communicable Diseases (NICD) 
from 2009-2014, to look at the past hepatitis A prevalence trend. Our cross-sectional study 
showed the seroprevalence to be 44.1% in the 1-7 year age group. The NHLS data showed 
a seroprevalence of <90% up to age 10 years, indicating intermediate endemicity. The NICD 
data showed that a substantial number of symptomatic hepatitis A infections occurred in the 
7-40 year age group, suggesting an increasing proportion of a susceptible population to HAV 
infection. Taken together, these results indicate the need for further studies designed to aid 
the development of vaccination policies against HAV infection in South Africa. 
 







Hepatitis A virus  (HAV) is responsible for approximately 1.4 million new infections each year 
(1-3). The virus is a member of the Hepatovirus genus of the family Picornaviridae, and is a 
non-enveloped single-stranded positive sense RNA virus (4, 5). 
Transmission of HAV is via the faecal-oral route, either through an infectious person, or by 
ingestion of contaminated food or water (4, 6). The risk factors for infection with HAV include 
low socioeconomic status, a larger household size and overcrowding in rural areas, limited 
access to clean water sources and sanitation facilities (1, 7).  
The geographic distribution of HAV infection is uneven worldwide, and the epidemiology is 
changing in some regions due to improved sanitation and living standards (8, 9). In modern 
urban populations a decrease in HAV prevalence has been noted, whereas in populations 
with poor or no sanitation and overcrowded living conditions infection occurs at an early age. 
In this context, close to 100% of children acquire infection in the first decade of life (8). In the 
past it was thought that South Africa was highly endemic for HAV infection, but currently the 
epidemiology in South Africa is unknown. 
Hepatitis A virus infection is vaccine preventable (10). The World Health Organization (WHO) 
2012 position paper on hepatitis A vaccines states that both the inactivated and live attenuated 
vaccines are safe and highly immunogenic, and that in most cases these vaccines will 
generate long-lasting, and possibly lifelong protection against HAV in both children and adults 
(10). The WHO recommends vaccination for children ≥ 1 year of age in counties of 
intermediate or low endemicity. Understanding the epidemiology of the HAV in South Africa is 
a prerequisite for the development of a vaccination policy for the disease. 
South Africa has shown marked improvement in water sources and sanitation facilities (11). 
We therefore propose that South Africa could be in an epidemiological transition. To 
investigate this, we performed a pilot cross-sectional seroprevalence study in young children. 
This study is part of the first author’s minor dissertation for a masters’ degree in Medical 
Virology at the University of Cape Town. We chose the Western Cape Province as the study 
site for convenience. 
2. Methods 
2.1 Study design 
We used a two pronged methodological approach: 
A. We conducted an observational cross-sectional study to examine the seroprevalence of 
hepatitis A in children between 1 and 7 years of age in the Western Cape Province of 
South Africa.  Serum samples sent for routine diagnostic testing were collected from 3 
Western Cape referral laboratories, and were tested for antibodies against HAV. The 
study population was stratified into 3 age groups:  1-2 years, 3-4 years and 5-7 years. 
B. We also conducted a retrospective review of hepatitis A laboratory results from 2 sources: 
hepatitis A IgG age specific prevalence from routine diagnostic samples submitted to 
Groote Schuur Hospital (GSH) National Health Laboratory Service (NHLS) Virology 
laboratory from 2009-2014, and surveillance data on acute hepatitis A virus infections in 
the Western Cape Province between 2009 and 2014 collected by the National Institute 




A. Seroprevalence study: 
2.1.1 Sample size 
Our hypothesis is that the Hepatitis A infection rates have dropped markedly in young children 
in the Western Cape due to improvements in hygiene standards and access to clean water.  
This would be reflected as a reduction in the seroprevalence particularly among  the 1-7 year 
olds. To determine an appropriate sample size that would enable an accurate assessment of 
hepatitis A seroprevalence in the study population, the following formula was used: 
Z1- /2 2 P(1-P) /d2 (12, 13)  
Z1- /2 2: is a measure of the level of confidence and describes the level of uncertainty in the 
sample prevalence as an estimate of the population prevalence. A value of 1.96 which reflects 
a 95% confidence Interval is recommended. 
P: The estimated prevalence within the target population. We hypothesized that an estimated 
50% of our study population would be seropositive for hepatitis A. Previously it was thought 
that the seroprevalence in South Africa was 90% or more. 
d: is the margin of error, which is the half width of the confidence interval. The larger the 
sample size, the smaller the margin. We used the recommended value of 0.05. 
Sample size= 1.96x1.96x0.5 / 0.05x0.05 = 384 (13) 
Based on an expected prevalence of about 50% in the study population and a margin of error 
of 5% (0.05), a sample size of 384 was deemed sufficient. 
2.1.2 Sample selection 
A total of 508 “left over” serum samples that were sent for routine diagnostic testing, from 
patients aged 1-7 years old presenting for routine or emergency medical treatment, was 
collected. Samples from 3 laboratories, collected between August 2015 and October 2015 
were tested. The  blood samples were drawn at primary and tertiary level health care facilities 
and then sent to the referral laboratories for the routine tests. Convenient sampling method 
was used for sample collection from the laboratories. Samples from patients with liver disease 
were excluded, and the HIV status of the patients as well as ethnicity, was not known.  
From these samples, 482 met our study inclusion criteria. We decided to use the 482 samples 
instead of the calculated 384 to accommodate for any potential equivocal results, as well as 
to maximise the use of the ELISA plates which could accommodate 92 samples per plate. The 
sources of the serum samples that were included are as follows: 41 from the Groote Schuur 
NHLS Virology laboratory, 265 from Red Cross Children’s Hospital and NHLS Chemistry and 
Haematology laboratories, and 176 samples from Tygerberg Hospital.  
On collection, the samples were numbered and stored in a -80ºC freezer at the NHLS Virology 
laboratory in Groote Schuur Hospital. The following demographic details of the patients’ serum 
samples were also collected: age, gender and residential location or referring clinics. Informed 
consent was not necessary to obtain as there was no direct contact with the patients, the 
results of the study did not impact patient treatment and ethics approval was obtained from 





2.1.3 Inclusion criteria 
1. Residents of the Western Cape Province (according to the demographic records) 
2. 1 – 7 years old  
3. Sera with a minimum volume of 100 l 
2.1.4 Exclusion criteria 
1. Samples from patients with documented acute hepatitis infection 
2.1.5 Research location 
Hepatitis A total antibody testing was performed at the NHLS diagnostic Virology laboratory in 
Groote Schuur Hospital. 
2.1.6 Procedure 
Samples were retrieved from the -80ºC freezer and thawed at room temperature. Testing was 
performed according to manufacturer’s instructions (14). Serum samples were tested for anti-
HAV total antibodies (IgG and IgM), using a manual enzyme immunoassay (Siemens 
Enzygnost anti-HAV), as per Siemens protocol (14).  
This is a competitive assay. The ELISA plate is coated with anti-hepatitis A antibody. 25 l of 
test sample and controls were used. There were 2 incubation steps, and the assay was read 
within an hour of stopping the reaction. Bio-Tek ELx800 ELISA reader was used and the assay 
was read at a wavelength of 450nm. 
Test samples with equivocal results were retested in duplicate, and remaining samples were 
stored at -80ºC. Anti-HAV total antibody results were entered on a Microsoft Excel 
spreadsheet, and stored on an access-controlled computer located at the NHLS Virology 
laboratory in Groote Schuur Hospital. 
B. Retrospective review 
 
1. Routinely collected hepatitis A anti-IgG antibody test results were extracted from the 
Groote Schuur Hospital National Health Laboratory Service (NHLS) database, from  
January 2009 to December 2014.These results were analysed to provide a retrospective 
review of the hepatitis A seroprevalence during that period. 
2. Also, acute hepatitis A surveillance data (anti-HAV IgM antibody results) routinely 
collected from public sector hospitals and clinics in the Western Cape Province by the 
National Institute for Communicable Diseases (NICD) between 2009 and 2014, was 
analysed.  
No patient identifiers were available from the routinely reported data that we used for our 
retrospective review analysis. Therefore, only basic demographic data for these samples is 
reported. 
2.2. Data analysis 
Data from the GSH NHLS laboratory database (anti-HAV IgG results, January 2009 – 
December 2014), as well as the hepatitis A surveillance data provided by the NICD (anti-HAV 
IgM results, 2009 – 2014) were analysed using SPSS version 23. SPSS version 23 was also 
used for the analysis of the current seroprevalence study. Equivocal test results were excluded 
from analysis. 
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For both the NHLS and NICD data sets we evaluated the hepatitis A trends from 2009 to 2014. 
All data was entered on a Microsoft Excel spreadsheet, and stored on an access-controlled 
computer at Groote Schuur Hospital (NHLS server). No patient identifiers were present, and 
no direct contact was made with the patients.  
2.3. Ethics 
Ethics approval was obtained from the University of Cape Town Human Research Ethics and 
University of Stellenbosch Ethics Committees (for samples collected from Tygerberg 
Hospital). Permission to conduct a study using samples from Red Cross Children’s Hospital 
was also obtained. 
3. Results  
3.1. Seroprevalence study 
Our first aim was to establish the seroprevalence of HAV among 1-7 year old children. To 
address this aim, we tested 482 serum samples that met our inclusion criteria. Of the total 
samples tested, 231 (47.9%) were females (Table 1).  
Seroprevalence, defined by the proportion of the serum samples that tested positive for total  
anti-HAV antibodies, was 44.1%( 212 out of 482). As expected, seroprevalence increased 
with age: 22.2% (45/203) for the 1-2 year old children, 51.7% (31/60) for the 3-4 year old 
children and 62.4% (136/218) in the 5-7 year old children. One serum sample test was 
equivocal (male, age 1), and even on repeat testing in duplicate, remained equivocal. This 




Participant gender, age groups and results of current study (anti-HAV total antibody). 
Gender and results 1-2 years 3-4 years 5-7 years Total 
Gender 









   Male n (%) 
 
112 (55.2) 24 (40) 114 (52.3) 250 (52.0) 
Total samples, n (%) 
 
Results 
203 (42.2) 60 (12.5) 218 (45.3) 481 (100) 
   Negative, n (%) 158 (77.8) 29 (48.3) 82 (37.6) 269 (55.9) 
   Positive, n (%) 45 (22.2) 31 (51.7) 136(62.4) 212 (44.1) 
Abbreviations: n, number. Fisher’s Exact test showed no significant statistical difference between males and 
females. 
 
The results obtained from the current study were plotted to show the median age distribution 
of children who were hepatitis A antibody positive and antibody negative (Figure 3).  The 
median age of antibody positive children was 4 years and that of antibody negative children 





Figure 3: Median age distribution of anti-HAV total antibody positive and negative individuals. The box plot 
demonstrating the negative and positive results, as well as the median age distribution of the 482 tested samples. 
The median age of positivity in the sample population is around 4 years of age, and no statistical difference is 




3.2. Retrospective study 
3.2.1 Hepatitis A seroprevalence from the NHLS GSH laboratory database from 2009-2014 
We displayed the NHLS data  from GSH as a heat map (Figure 4) showing the seroprevalence 
in small age increments, namely 1-2 years, 3-4 years, 5-7 years, 8-10 years, 11-15 years, 16-
20 years, 21-25 years, 26-30 years, 31-35 years, 36-40 years, and >40 years. A 3-colour scale 
was used: purple-to-white-to-green to indicate increasing seroprevalence.  The minimum 
(lowest value): purple; midpoint (50th percentile): white; maximum (highest value): green. 
Seropositive percentages < 50% are displayed in white font, as well as percentages ≥ 90%.  
A seroprevalence of  50% by age 15 years, but < 90% by age 10 years, is noted in all years 
(intermediate endemicity as defined by the WHO). Of note the seroprevalence was 
consistently < 90% under the age of 10 for all calendar years. This suggests that hepatitis A 









years 2009 2010 2011 2012 2013 2014 
1-2  56 46 25 47 46 56 
3-4  65 56 79 62 56 65 
5-7  66 73 78 82 77 73 
8-10  72 77 85 74 77 78 
11-15 79 81 84 72 80 75 
16-20  83 93 84 78 89 75 
21-25  77 71 79 85 88 85 
26-30  76 81 88 88  83 83 
31-35  82 84 83 90 83 90 
36-40  85 89 90 91 95 87 
> 40  89 90 92 95 95 93 
Figure 4. Heat map of the positive NHLS GSH hepatitis A IgG results 2009-2014. The total number of samples 
tested from 2009 – 2014 was 2456, 2207, 2182, 2287, 2244, 2318 respectively. Pearson Chi Square test showed 
no statistical difference between samples tested per year. The positive hepatitis A IgG results that were extracted 
from GSH NHLS database (Disa*Lab) from 2009-2014, are reflected as a percentage and are stratified into the 
following groups: 1-2 years; 3-4 years; 5-7 years; 8-10 years; 11-15 years, 16-20 years; 21-25 years; 26-30 years, 
31-35 years; 36-40 years, and >40 years. A 3 colour scale was used: purple-to-white-to-green. Minimum (lowest 
value): purple; midpoint (50th percentile): white; maximum (highest value): green. Seropositive percentages < 50% 
are displayed in white font, as well as percentages ≥ 90%. Of note is the seroprevalence is < 90% by age 10 from 
2009-2014. 
 
3.2.2. Review of acute hepatitis A surveillance data from the Western Cape 2009-2014 
The results analysed and displayed in Figure 5 are a summary of the surveillance data 
provided by the NICD, and reflects the hepatitis A IgM positive tests from 2009–2014, showing 
a peak increase in positivity of around age 6. 
The positive hepatitis A IgM results that were recorded from hospitals in the Western Cape 
from 2009-2014, provided by the NICD, are also displayed in Figure 6. We grouped the results 
from the patients into 3 categories: 1-6 years, 7-40 years and > 40 years and plotted them 
according to each calendar year. Across all years, the highest number of clinical hepatitis A 
cases was in the 7-40 year age group.  Cases in the >40 year age group were very few 
accounting for only 4.2% of the total positives in 2009, 2.5% in 2010, 3% in 2011, 6.5% in 






Figure 5. Age distribution of the NICD Western Cape hepatitis A surveillance data. The positive hepatitis A IgM 
results  were provided by the NICD collected from Western Cape clinics and hospitals, and shows an increase in 




Figure 6. NICD hepatitis A IgM Western Cape Province surveillance data. These are results collected by the NICD 
from various clinics and hospitals in the Western Cape Province. The results are displayed are absolute numbers 
of positive tests and not percentages as the total number of tested samples per age group( positive and negative) 
was not made available. We grouped the results from the patients into 3 groups: 1-6 years, 7-40 years and > 40 
years.  Cases in the >40 year age group across all years were very few. The highest number of clinical hepatitis A 
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3. Discussion  
Our cross-sectional study, the samples of which were collected between August and October 
2015, indicate a seroprevalence of 44.1% in the 1-6 age group, suggesting that South Africa 
may be undergoing an epidemiological transition of HAV infection. The retrospective study 
using the NHLS GSH data also reflects intermediate endemicity, while the analysis of the 
NICD data displays  an increase of symptomatic of hepatitis A infection in the 7-40 year age 
group. These results indicate a possible epidemiological change of HAV infection. We 
propose that better designed studies be prioritized in the future to guide the development of 
vaccination policies against HAV infection in the country. 
According to a WHO position paper on hepatitis A vaccines , levels of endemicity are classified 
as follows: high (≥90% by age 10 years), intermediate  (≥50% by age 15 years, with <90% by 
age 10 years), low (≥50% by age 30 years, with <50% by age 15) and very low (<50% by age 
30 years) (15). In the past South Africa was considered to be highly endemic for hepatitis A, 
as it was thought that most children were exposed to the virus by the age of 6 (4, 16). Our 
cross-sectional data suggest otherwise as we showed a seroprevalence of 44% among 1-
7years old. 
Our results indicating intermediate HAV endemicity could be explained by a few factors. First,  
South Africa has shown marked improvement in water sources and sanitation facilities in the 
last two and a half decades (11). Second, there has been socioeconomic development in 
resource-poor regions, and improved hygiene. Together, these factors, may lead to change 
from a high HAV endemicity pattern to an intermediate endemicity pattern, and this is known 
as “epidemiologic transition” (17). This is because hepatitis A is enterically transmitted and as 
hygiene improves, children can be expected to be exposed less frequently, and acquire 
infection at a later age.  Thus the seroprevalence, which reflects past infection, declines in 
young children.  
For our cross-sectional study we tested children attending public health facilities in the Cape 
Town area. We found the seroprevalence to be 44.1% in the total study population, ages 1-7. 
This shows a shift from the previously high seroprevalence (almost 100%) reflected in the 
studies done (4, 16) in the past, however these study populations may not be directly 
comparable. The 1993 study conducted by Abdool Karim looked at seroprevalence in Durban, 
limited to the black urban population from newborn to 13 years of age and the results showed 
that the seroprevalence in this age group in SA was almost 100% (by age 6).  
More than 50% were already infected by the age of 4 in our cross-sectional study, which 
indicates that early hepatitis A infection remains high, and is likely to be higher still in more 
rural environments. More studies need to be conducted in the more rural areas, and should 
be extended to the rest of the country to correctly describe the seroprevalence. 
We were not privy to the socio-economic status of the subjects tested or their accessibility to 
clean water sources. However, our selected population may well be representative of an 
“average SA household”. According to the data available on the World Bank, in 1990 only 38% 
of the rural population in South Africa had access to sanitation facilities, and this improved to 
61% by 2015. In contrast 64% of the urban population had access to sanitation facilities in 
1990, and this increased to 70% by 2015 (11). Access to clean water also varies:  in 1990, 
66% of the rural population had access to water sources and this increased to 81% by 2015, 
as opposed to 98% of the urban population in 1990, and 100% by 2015 (11). 
The NHLS data from GSH reflected a seroprevalence of < 90% by age 10, indicating 
intermediate endemicity from as early as 2009. There was minimal variation through all the 
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age groups from 2009-2014. Our analysis of the NICD data on acute hepatitis A virus 
infections revealed an increased number of symptomatic infections in the 7-40 year group, 
however the peak age of symptomatic infection is seen at age 6. This demonstrates that 
adolescents are particularly vulnerable to symptomatic hepatitis A in the Western Cape.  
A similar trend was noted in a recent systematic review of hepatitis A seroprevalence in Middle 
East and North Africa region (MENA) (18). One of the studies mentioned in this review, was 
conducted in Saudi Arabia and demonstrated a decline in HAV prevalence reported among 
Saudi children and adolescents over a 20 year period, from 52% in 1989 to 25% in 1997 to 
18.6% in 2008.  In another study, Memish et al looked at trends in Saudi Arabia from 2000-
2007, and reported 20-30% declining trends. HAV incidence decreased by 42% in the < 15 
year olds and increased by 61% in the > 15 year olds (19). Another study mentioned in the 
systematic review looking at seroprevalence in MENA countries was conducted in Tunisia 
(2000-2007), where the prevalence was documented as follows: 91.9% and 80.6% in 2000 
and 2007 among the 18-20 year olds, verses seroprevalence of 99% and 92% in adults > 26 
years of age (20). This study highlighted the susceptibility of adolescents and young adults to 
HAV. Recent epidemiological studies in India have also shown a decline in hepatitis A 
seroprevalence among younger children and an increasing susceptibility in the older children 
and young adults (21), a trend we observed in our study.  
A possible explanation for the higher seroprevalence displayed in the NHLS data from GSH 
as compared to our cross-sectional study could be that the NHLS  data contained results from 
individuals that were being screened for hepatitis A immunization status, for example children 
who were vaccinated and awaiting liver transplants. This could have inflated the 
seroprevalence in this age group. Nonetheless the NHLS data also revealed that the 
seroprevalence was < 90% by age 10, and ≥ 50% by age 15 from 2009-2014, which fits the 
definition of intermediate endemicity as defined by the WHO (15). 
The observed increase in average age of infection is a concern because it is associated with 
increased morbidity and mortality due to hepatitis A (17, 18, 22). Because of this the WHO 
recommends integration of the hepatitis A vaccine into the national immunization schedule for 
children ≥ 1 year of age in counties of intermediate or low endemicity.  It is an expensive 
vaccine and it is not cost effective in areas of high endemicity (15). We propose that the 
younger susceptible population may benefit from the integration of the hepatitis A vaccine into 
the national vaccine schedule in South Africa. 
5. Limitations 
There were study limitations, particularly with the retrospective NHLS data as well as the NICD 
surveillance data. The retrospective data only included samples that were sent to the 
laboratory for testing, and therefore does not represent the population as a whole. Many of 
the patients from the retrospective data were also being actively screened for viral hepatitis. 
The results from the current study also only include samples sent to the laboratory for routine 
testing from an urban setting in the Western Cape Province, and therefore does not represent 
the population as a whole. The samples that were tested for hepatitis A total antibodies only 
represent the public sector in South Africa, as we did not obtain samples from the private 
laboratories. We did not have data regarding the socioeconomic conditions of the patients 
whose sera were used in the current study. More studies need to be conducted especially in 





The results obtained from the current study reflect a hepatitis A seroprevalence of 44% in   the 
1-7 year old population. The NHLS data reflects intermediate endemicity from 2009-2014.The 
surveillance (NICD) data reflects that most of the symptomatic hepatitis A infections occurred 
in the 7-40 year age group in the Western Cape Province. This pilot study highlights the need 
for further studies to determine whether a change regards the hepatitis A vaccination policy is 
required. These studies should be extended to the rest of the country, including rural areas. 
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1.2 Does this protocol receive US Federal funding? D Yes ,1 No 
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Ethics Reference #: S15/08/173
Clinical Trial Reference #:
Title: Hepatitis A seroprevalence in South Africa. Are we in epidemiological transition?
 
Dear Dr Annabel Enoch,
 
We acknowledge receipt of documents pertaining to the above study and the approval letter from the UCT Health Sciences REC for
this project.
The approval of the UCT HREC is recognised by the Stellenbosch University HREC for this particular project. Review by the
Stellenbosch University HREC is therefore not required.
However please continue to keep us informed of the progress of the project, by submitting annual progress reports.
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Dr A Enock 
Dr R Mistry 
Manager: Medical Services 
Email: Roshni.Mistry@westerncope.gov .zo 
Tel: +27216585788 fox: +27216585166 
Red Cross War Memorial Children's Hospital 
Dear Dr A Enock 
APPROVAL OF RESEARCH 
PROJECT TITLE: HEPATITIS.A SEROPREVALENCE IN SOUTH AFRICA. ARE WE IN 
EPIDEMIOLOGICAL TRANSITION ? 
We hove the pleasure of informing you that approval is hereby gronled to conduct the 
above-mentioned study at Red Cross War Memorial Children's Hospital. 
DR ROSHN M 
MANAGER: MEDICAL SERVICES 
DATE: 03 AUGUST 2015 
www.westerncope.gov.zo 
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